

# **Morgan Lewis**




## **BLOCKBUSTER BIOLOGICS REVIEW ISSUE 14** *Inter Partes* Reviews (IPRs) and Litigations




### > Quick statistics:

- The current institution rate for IPR challenges to patents that claim biologics is 38% (excludes IPRs that have settled or otherwise been terminated)
- > Of those IPRs instituted and that have gone to final written decision (FWD), 43% have resulted in the challenged claims being held unpatentable, with 60% having mixed results

### **IPRs by Reference Product**



### **IPR Timeline**




US Patent and Trademark Office (USPTO) (Fiscal Year: October–September)

Morgan Lewis

4

### **Types of Claims Being Challenged**



### **IPR Scorecard – Institution**

<b>Product</b> (# of IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.*
	Amgen	0	2	-	-
Humira (22)	Boehringer Ingelheim	0	-	-	2
nuillia (22)	Coherus	0	5	2	3
	Sandoz	0	6	2	-
	Boehringer Ingelheim	0	1	2	-
Rituxan (27)	Celltrion	0	6	2	3
	Pfizer	0	5	3	3
	Sandoz	0	2	-	-
	Phigenix	0	1	-	1
	Mylan	0	-	2	-
	Hospira	0	1	-	5
Herceptin (36)	Celltrion	0	-	1	6
	Pfizer	0	5	2	4
	Samsung	0	1	-	5
	Boehringer Ingelheim	0	-	2	-
Tysabri (3)	Swiss Pharma	0	3	-	-

### **IPR Scorecard – Institution** (cont.)

Product (# of IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.*
Avastin (2)	Hospira	0	1	-	1
Orencia (1)	Momenta	0	-	-	1
	Apotex	0	-	-	1
	Fresenius Kabi	0	1	2	-
Neulasta (8)	Kashiv Biosciences	0	-	2	-
	Lupin	0	1	-	-
	Hospira	0	-	-	1
Enbrel (3)	Kyle Bass	0	1	-	-
	Coherus	0	2	-	-
Epogen (1)	Hospira	0	-	1	-
Keytruda (4)	Merck	0	0	4	-
Dupixent (3)	Sanofi-Aventis	0	1	-	2
Soliris (3)	Amgen	0	0	-	3
Insulin Glargine (2) Mylan		0	0	-	2
тот	ALS	0	45	27	43

#### *Institution rate = 43/114 = 38%*

\* IPRs instituted but later settled or otherwise terminated are not included

### **IPR Scorecard – Final Written Decisions (FWDs)**

Product (# of IPRs)	Challenger	Inst.*	FWD (invalid)	FWD (upheld)	Mixed
	Amgen	-	-	-	-
Humira (22)	Boehringer Ingelheim	2	2	-	-
nulliid (22)	Coherus	3	3	-	-
	Sandoz	-	-	-	-
	Boehringer Ingelheim	-	-	-	-
Rituxan (27)	Celltrion	3	1	1	-
Kiluxali (27)	Pfizer	3	1	1	-
	Sandoz	-	-	-	-
	Phigenix	1	-	1	-
	Mylan	-	-	-	-
	Hospira	5	3	2	-
Herceptin (36)	Celltrion	6	2	2	2
	Pfizer	4	1	-	2
	Samsung	5	1	2	2
	Boehringer Ingelheim	-	-	-	-

### IPR Scorecard – FWDs (cont.)

Product (# of IPRs)	Challenger	Inst.*	FWD (invalid)	FWD (upheld)	Mixed
Tysabri (3)	Swiss Pharma	-	-	-	-
Avastin (2)	Hospira	1	1	-	-
Orencia (1)	Momenta	1	-	1	-
	Apotex	1	-	-	1
Neulasta (5)	Fresenius Kabi	1	-	-	-
	Kashiv Biosciences	2	-	-	-
Enbrel (3)	Kyle Bass	-	-	-	-
	Coherus	-	-	-	-
Epogen (1)	Hospira	-	-	-	-
Keytruda (4)	Merck	-	-	-	-
Dupixent (3)	Sanofi-Aventis	2	1	1	-
Insulin Glargine (2) Mylan		2	2	-	-
тот	ALS	42	18	11	7

#### Invalidation rate = 18/42 = 43%, with mixed results 60%

\* IPRs instituted but later settled or otherwise terminated are not included

### **Blockbuster Biologics: IPR Appeals (Humira)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
AbbVie	Coherus	8,889,135	2016-00172 (2017-2304)	Claims Invalid	All of these appeals have been consolidated
AbbVie	Boehringer Ingelheim	8,889,135	2016-00408 (2017-2362)	Claims Invalid	<ul> <li>Federal Circuit affirmed five FWDs, finding claims unpatentable as obvious</li> </ul>
AbbVie	Boehringer Ingelheim	8,889,135	2016-00409 (2017-2363)	Claims Invalid	
AbbVie	Coherus	9,017,680	2016-00188 (2017-2305)	Claims Invalid	
AbbVie	Coherus	9,073,987	2016-00189 (2017-2306)	Claims Invalid	

### **Blockbuster Biologics: IPR Appeals (Rituxan)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Celltrion	7,820,161	2016-1614 (2018-1885) 2017-01115 joined (2018-1924)	Claims Valid	<ul> <li>Appeal No. 2016-1614 voluntarily dismissed</li> <li>Appeal No. 2018-1885 dismissed with prejudice as part of Settlement and License Agreement</li> <li>Appeal No. 2018-1924 dismissed as part of litigation settlement (Case No. 18-574-RMB-KMW (D.N.J.))</li> </ul>
Biogen	Pfizer	8,821,873	2017-01168 (2019-1364)	Claims Invalid	<ul> <li>Biogen challenging constitutionality of IPRs</li> <li>Pfizer not participating in appeal</li> <li>USPTO intervened in appeal</li> <li>Parties voluntarily dismissed appeal</li> <li>Issues fully briefed</li> <li>Affirmed Board's decision</li> </ul>

### **Blockbuster Biologics: IPR Appeals (Herceptin)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,807,799	2016-01837 (2018-1933)	Claims Invalid	<ul> <li>USPTO intervened</li> <li>Affirmed Board's decision that challenged claims as unpatentable on anticipation and obviousness grounds</li> </ul>
Genentech	Hospira	7,846,441	2017-00731 (2019-1263)	Claims Invalid	<ul> <li>Hospira withdrew as party due to settlement, and USPTO intervened</li> <li>Lead case – consolidated with 2019-1267</li> <li>Appeal submitted on briefs</li> <li>Affirmed Board's decision that challenged claims as unpatentable on obviousness grounds</li> </ul>
Genentech	Celltrion	7,846,441	2017-01121 (2019-1267)	Claims Invalid	<ul><li>USPTO intervened</li><li>Consolidated with 2019-1263</li><li>Affirmed Board's decision</li></ul>
Genentech	Hospira	6,627,196	2017-00804/ 2017-01958 joined (2019-1173)	Claims Valid	<ul> <li>Lead case – consolidated with 2019-1174</li> <li>Appeal voluntarily dismissed</li> </ul>

### Blockbuster Biologics: IPR Appeals (Herceptin) (cont.)

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,371,379	2017-00805/ 2017-01959 joined (2019-1174)	Claims Valid	<ul><li>Consolidated with 2019-1173</li><li>Appeal voluntarily dismissed</li></ul>
Genentech	Celltrion	6,627,196	2017-01139 (2019-1258)	Claims Valid	<ul><li>Consolidated with 2019-1259</li><li>Parties dismissed appeal</li></ul>
Genentech	Celltrion	7,371,379	2017-01140 (2019-1259)	Claims Valid	<ul><li>Consolidated with 2019-1258</li><li>Parties dismissed appeal</li></ul>
Genentech	Hospira	7,892,549	2017-00737/ 2017-01960 joined (2019-1265)	Claims Invalid	<ul> <li>Hospira withdrew as party due to settlement</li> <li>Samsung Bioepis withdrew as party</li> <li>Lead – consolidated with 2019-1270</li> <li>Affirmed Board's decision that challenged claims as unpatentable on obviousness grounds</li> </ul>
Genentech	Celltrion	7,892,549	2017-01122 (2019-1270)	Claims Invalid	<ul><li>USPTO allowed to intervene</li><li>Affirmed Board's decision</li></ul>

### **Blockbuster Biologics: IPR Appeals (Neulasta)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Amgen	Apotex	8,952,138	2016-01542 (2019-2171)	Claims Invalid	<ul> <li>Amgen filed Notice of Appeal</li> <li>USPTO allowed to intervene</li> <li>Amgen raised Appointments Clause challenge</li> <li>Board's decision vacated and case remanded to Board for proceedings consistent with court's decision in <i>Arthrex</i></li> </ul>

### **Blockbuster Biologics: IPR Appeals (Avastin)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,622,115	2016-01771 (2018-1959)	Claims Invalid	<ul> <li>Includes constitutional challenge regarding retroactive application of IPR to pre-AIA patent</li> <li>United States intervened</li> <li>Oral argument held July 11, 2019</li> <li>Judgment affirmed</li> </ul>

### **Blockbuster Biologics: IPR Appeals (Orencia)**

Patent Owner	Challenger	Patent No.	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Bristol-Myers Squibb	Momenta	8,476,239	2015-01537 (2017-1694)	Claims Valid	<ul> <li>Federal Circuit dismissed appeal for lack of standing/jurisdiction and for mootness</li> </ul>

### **Post-Grant Reviews (PGRs)**

 Only one PGR has been filed to date in connection with a blockbuster biologic (US 9,856,287)

<b>Product</b> (# IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.
Neupogen (1)	Adello/Apotex	-	-	-	1

# US BIOSIMILAR-RELATED PATENT LITIGATIONS

### > Enbrel Litigation: *Immunex v. Samsung Bioepis*

- > On November 3, 2021, Final Judgment and Order of Permanent Injunction entered against Samsung Bioepis in District Court of New Jersey
  - > Permanent injunction will terminate on April 24, 2029 when patents expire
- > Court had administratively stayed the case in January 2020

### US Biosimilar Litigations: Developments (cont.)

#### > Summary of Nine Humira Biosimilar Settlements

Party	US Market Entry	EP Market Entry
Amgen	January 31, 2023	October 16, 2018
Biogen and Samsung Bioepis	June 30, 2023	October 16, 2018
Mylan	July 31, 2023	
Sandoz	September 30, 2023	October 16, 2018
Fresenius Kabi	September 30, 2023	Upon approval
Momenta	November 20, 2023	
Pfizer	November 20, 2023	
Coherus	December 15, 2023	
Boehringer Ingelheim	July 1, 2023	

### US Biosimilar Litigations: Developments (cont.)

### > Products in patent litigation that we are monitoring include:

Neupogen

Remicade

>

>

- > Avastin > Herceptin
- > Enbrel > Humira
- > Epogen > Neulasta
- > These litigations are summarized on the following slides

### **Blockbuster Biologics: US Litigation Scorecard – Humira**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims*	Status
	AbbVie v. Amgen	No. 16-666-MSG (D. Del.)	10	M, F, U, C	<ul> <li>Settled – US launch of Amjevita expected January 31, 2023</li> </ul>
	AbbVie v. Boehringer Ingelheim	No. 17-1065-SLR (D. Del.)	8	M, F, U, C	<ul> <li>Parties stipulated to dismissal</li> </ul>
Humira (7)	AbbVie v. Sandoz	No. 18-12668 (D.N.J.)	2	U, F	<ul> <li>Settled – US launch of Hyrimoz expected September 20, 2023</li> </ul>
	Coherus v. Amgen	No. 19-00139 (D. Del.)	3	С	<ul> <li>Parties stipulated to dismissal</li> <li>Amgen's filed motion for determination of exceptional case and award of fees denied</li> </ul>

\*See slide 59 for legend of abbreviations.

### Blockbuster Biologics: US Litigation Scorecard – Humira (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims*	Status
Humira (7)	AbbVie v. Alvotech	No. 21-2258 (N.D. Ill.)	4	F, M, U	<ul> <li>Court denied motion to dismiss on August 23, 2021 and entered a scheduling order on September 20, 2021</li> <li>Trial set for August 2022 and court plans to issue trial decision by end of October 2022</li> <li>Defendant agreed not to launch in the US until after court's trial decision</li> </ul>
	Alvotech v. AbbVie	No. 21-00265 (E.D. Va.)	4	F, M, U	<ul> <li>October 22, 2021, E.D. Va. court transferred case to the N.D. Ill.</li> <li>Dismissed AbbVie's pending motion to dismiss as moot</li> </ul>
	AbbVie v. Alvotech	No. 21-02899 (N.D. Ill.)	58	F, M, U	Complaint filed May 28, 2021

\*See slide 59 for legend of abbreviations.

### **Blockbuster Biologics: US Litigation Scorecard – Rituxan**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Sandoz	No. 17-13507-RMB-KMW (D.N.J.)	24	M, U, C	<ul> <li>Stipulated dismissal without prejudice</li> <li>Sandoz decided not to pursue its FDA submission for its biosimilar</li> </ul>
<b>Rituxan</b> (4)	Celltrion v. Genentech	No. 18-276-JSW (N.D. Cal.) No. 18-2161 (Fed. Cir.) (consolidated with No. 18-2160)	37	M, U	<ul> <li>Genentech's Motion to Dismiss granted</li> <li>Final judgment appealed to Federal Circuit</li> <li>Appeal voluntarily dismissed</li> </ul>
	Genentech v. Celltrion	No. 18-574-RMB-KMW (D.N.J.)	40	M, U, C	• Settled
	Genentech v. Celltrion	No. 18-11553 (D.N.J.) (consolidated with No. 18-574-RMB-KMW)	18 (Claims mirror those of No. 18-574-RMB-KMW– filed to ensure compliance with BPCIA)	M, U, C	• Settled

### **Blockbuster Biologics: US Litigation Scorecard – Herceptin**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Celltrion v. Genentech	No. 18-274-JSW (N.D. Cal.) No. 18-2160 (Fed. Cir.)	38	M, U, C	<ul> <li>Genentech's Motion to Dismiss granted</li> <li>Final judgment appealed to Federal Circuit</li> <li>Appeal voluntarily dismissed</li> </ul>
Herceptin (6)	Genentech v. Celltrion	No. 18-095-CFC (D. Del.)	40	M, U, C	<ul> <li>All Delaware cases are before Judge Connolly and being coordinated</li> <li><i>Markman</i> hearing April 2019</li> <li>Trial in December 2019</li> <li>Lead case</li> <li>Settled</li> </ul>
	Genentech v. Pfizer	No. 17-1672-CFC (D. Del.)	40	M, U, C	Settled

### **Blockbuster Biologics: US Litigation Scorecard – Herceptin** (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Amgen	No. 18-924-CFC (D. Del.)	37	M, U, C	<ul> <li>Parties stipulated to dismissal on July 7, 2020</li> </ul>
Herceptin (6)	Genentech v. Celltrion	No. 18-1025-CFC (D. Del.)	40	M, U, C	Settled
	Genentech v. Samsung Bioepis	No. 18-01363-CFC (D. Del.)	21	M, U, C	Dismissed due to settlement

### **Blockbuster Biologics: US Litigation Scorecard – Neupogen**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neupogen (7)	Amgen v. Sandoz	No. 14-04741-RS (N.D. Cal.) No. 15-1499 (Fed. Cir.) Nos. 15-1039, 15-1195 (Supreme Court) No. 18-1551 (Fed. Cir.)	1	Μ	<ul> <li>Complaint alleged Sandoz violated BPCIA by (1) failing to provide its aBLA and manufacturing information within 20 days of FDA acceptance and (2) providing notice of commercial marketing before FDA approval of its aBLA</li> <li>District court ruled in favor of Sandoz; on appeal, Federal Circuit and Supreme Court did the same</li> <li>District court subsequently granted Sandoz's Motion for Summary Judgment of Noninfringement; affirmed on appeal</li> <li>Petition for rehearing en banc denied</li> </ul>
	Amgen v. Apotex	No. 15-62081-JIC (S.D. Fla.)	2	М, С	<ul> <li>Consolidated with Amgen v. Apotex pegfilgrastim (Neulasta) litigation, No. 15-61631, where district court entered judgment of noninfringement for Sandoz</li> <li>Affirmed</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Neupogen (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neupogen (7)	Amgen v. Kashiv	No. 18-3347-JMV-SCM (D.N.J.)	17	Μ	<ul> <li>Amended Complaint filed, reducing number of patents to four and naming Amneal Pharmaceuticals as co-defendant</li> <li>Amneal moved to dismiss Amended Complaint for failure to state claim and lack of subject-matter jurisdiction</li> <li>Claim construction briefed</li> <li>June 10, 2019, Kashiv substituted in place of Adello</li> <li>November 25, 2019, parties stipulated to dismissal without prejudice</li> </ul>
	Amgen v. Hospira	No. 18-1064 (D. Del.)	1	Μ	<ul> <li>Parties stipulated to dismiss all claims and counterclaims with prejudice</li> </ul>
	Sandoz v. Amgen	No. 19-00977 (N.D. Cal.)	1	Μ	<ul> <li>Sandoz voluntarily dismissed action without prejudice</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Neupogen (cont.)

	<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Amgen v. Tanvex	No. 19-1374-AJB-MSB (S.D. Cal.)	1	Μ	<ul> <li>Complaint and Answer to Complaint filed</li> <li>December 19, 2019, parties entered into stipulation of dismissal without prejudice</li> </ul>	
	Neupogen (7)	Amgen v. Hospira	No. 20-561 (D. Del.)	1	Μ	<ul> <li>Parties filed stipulation of dismissal with prejudice</li> </ul>

### **Blockbuster Biologics: US Litigation Scorecard – Neulasta**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta (7)	Amgen v. Apotex	No. 15-61631-JIC (S.D. Fla.) No. 16-1308 (Fed. Cir.) No. 17-1010 (Fed. Cir.) No. 16-332 (Supreme Court)	2	M, F	<ul> <li>Amgen found not to infringe</li> <li>Supreme Court denied Apotex's Petition for Certiorari</li> <li>Federal Circuit affirmed district court ruling</li> <li>District court: <ol> <li>granted Amgen's Motion for Summary Judgment re: invalidity defenses except nonenablement</li> <li>awarded judgment of noninfringement for Apotex</li> <li>dismissed Apotex's nonenablement defense without prejudice</li> </ol> </li> </ul>
	Amgen v. Sandoz	No. 16-1276-SRC-CLW (D.N.J.)	Litigation over whether Sandoz violated BPCIA	NA	<ul> <li>Dismissed after Sandoz restarted patent dance negotiations</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Neulasta (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta (7)	Amgen v. Sandoz	No. 16-02581-RS (N.D. Cal.) No. 18-1552 (Fed. Cir.) (consolidated with No. 18-1551)	2	M, F	<ul> <li>On appeal, fully briefed, pending scheduling of oral argument</li> <li>Summary Judgment of Noninfringement granted for Sandoz</li> <li>Affirmed</li> </ul>
	Amgen v. Coherus	No. 17-546-LPS (D. Del.) No. 18-1993 (Fed. Cir.)	1	М	<ul> <li>Court granted Coherus's Motion to Dismiss for Failure to State a Claim</li> <li>Judgment entered against Amgen, and case was dismissed</li> <li>Affirmed</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Neulasta (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta (7)	Amgen v. Mylan	No. 17-1235-MRH (W.D. Pa.)	2	Μ	<ul> <li>Claim Construction Order issued</li> <li>Amgen ordered to file, with infringement contentions, a statement identifying facts relied on outside of Mylan's FDA filings</li> <li>Motion for Summary Judgment of Noninfringement of US Patent No. 9,643,997 filed – ruling deferred</li> <li>Abeyance in place pending further order to be issued around August 14, 2019</li> <li>Parties stipulated to noninfringement of US Patent No. 9,643,997</li> </ul>
	Amgen v. Apotex	No. 18-61828 (S.D. Fla.)	1	Μ	<ul> <li>District court denied Apotex's motion to dismiss Amgen's complaint for failure to state a claim</li> <li>Joint Claim Construction Statement filed</li> <li>Accord Biopharma substituted in place of Apotex as defendant in August 2019</li> <li>November 14, 2019, parties entered into stipulation of dismissal without prejudice</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Neulasta (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta (7)	Amgen v. Hospira	No. 20-201 (D. Del.)	1	М	<ul> <li>Complaint filed February 11, 2020</li> <li>Hospira and Pfizer filed Motion to Dismiss for Failure to State a Claim, arguing that Amgen surrendered subject matter during prosecution</li> <li>Motion to Dismiss denied</li> <li>Case stayed following claim construction order until decision made as to whether early summary judgment practice as to noninfringement should be entertained</li> </ul>

### **Blockbuster Biologics: US Litigation Scorecard – Enbrel**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Entrol (2)	Immunex v. Sandoz	No. 16-01118-CCC-JBC (D.N.J.) No. 20-1037 (Fed. Cir.)	5	C, F, U	<ul> <li>Before trial, Sandoz stipulated to infringement to certain asserted claims of two of the five patents-in-suit</li> <li>Bench trial held September 2018 and district court judge ruled in favor of Immunex, holding patents-in-suit were valid</li> <li>Sandoz appealed to Federal Circuit</li> <li>Federal Circuit affirmed on July 1, 2020</li> <li>Petition for rehearing en banc denied</li> </ul>
Enbrel (2)	Immunex v. Samsung Bioepis	No. 19-11755-CCC (D.N.J.)	5	C, U, M, F	<ul> <li>Court entered Final Judgment and Permanent Injunction against Samsung Bioepis on November 3, 2021</li> <li>Permanent injunction in effect until April 24, 2029 when patents expire</li> </ul>

### **Blockbuster Biologics: US Litigation Scorecard – Epogen**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
<b>Epogen</b> (1)	Amgen v. Hospira	No. 15-839-RGA (D. Del.) No. 16-2179 (Fed. Cir.) (appeal was dismissed) No. 19-1067 and No. 19-1102 (Fed. Cir.)	2	С, М	<ul> <li>Jury found infringement and awarded \$70M in damages</li> <li>Final judgment entered with pre- and post-judgment interest</li> <li>Hospira appealed, arguing that all of its batches of product should be subject to safe-harbor provision about which jury was given erroneous instructions</li> <li>Amgen responded that there was sufficient evidence supporting jury's finding that only seven of 21 drug batches qualified for safe harbor</li> <li>Oral argument held September 30, 2019</li> <li>Judgment affirmed December 16, 2019</li> <li>Petition for Rehearing and Petition for Rehearing En Banc denied</li> </ul>

### **Blockbuster Biologics: US Litigation Scorecard – Avastin**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Amgen	No. 17-165-GMS (D. Del.)	Litigation over violations of BPCIA	NA	<ul> <li>Dismissed complaint without prejudice</li> </ul>
	Amgen v. Genentech	No. 17-7349-GW-AGR (C.D. Cal.)	27	M, C, F, U	<ul> <li>Genentech's Motion to Dismiss for Lack of Subject-Matter Jurisdiction granted</li> </ul>
<b>Avastin</b> (8)	Genentech v. Amgen	No. 17-1407-CFC (D. Del.)	24	M, C, F, U	<ul> <li>Consolidated with No. 17-1471</li> <li>Lead case</li> <li>Granted Genentech's motion to dismiss Amgen's counterclaims, seek declaratory judgment that two patents are invalid, unenforceable, not infringed for lack of subject-matter jurisdiction</li> <li>Joint Stipulation of Dismissal filed on July 7, 2020</li> </ul>
	Genentech v. Amgen	No. 17-1471-CFC (D. Del.)	25	M, C, F, U	Consolidated with No. 17-1407
	Genentech v. Pfizer	No. 19-00638-CFC (D. Del.)	22	M, C, F, U	Settled

### **Blockbuster Biologics: US Litigation Scorecard – Avastin** (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Avastin (8)	Genentech v. Immunex and Amgen	No. 19-00602-CFC (D. Del.) No. 19-2155 (Fed. Cir.)	14	M, C, F, U	<ul> <li>Genentech's motion to enforce statutory prohibition on commercial marketing and TRO denied</li> <li>Federal Circuit denied Genentech's Motion for an Injunction Pending Appeal</li> <li>Genentech appealed regarding commercial marketing</li> <li>Federal Circuit affirmed</li> </ul>
	Genentech v. Samsung Bioepis	No. 20-cv-00859 (D. Del.)	14	M, C, F, U	Complaint filed June 28, 2020
	Genentech v. Centus	No. 20-cv-00361 (E.D. Tex.)	10	M, U	<ul> <li>Complaint filed November 12, 2020</li> <li>Parties filed Joint Motion to Stay all Deadlines and Notice of Settlement</li> <li>Motion to dismiss with prejudice granted due to parties' settlement</li> </ul>

### **Blockbuster Biologics: US Litigation Scorecard – Remicade**

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Remicade (5)	Janssen v. Celltrion	No. 15-10698-MLW (D. Mass.) No. 17-1120 (Fed. Cir.)	2	C, U	<ul> <li>Partial Summary Judgment of Invalidity granted with respect to one patent ('471 patent)</li> <li>Federal Circuit dismissed appeal as moot upon affirming decision in appeal (No. 17-1257) from ex parte reexamination ruling by USPTO that same patent's claims are unpatentable for double patenting</li> <li>Dismissed without prejudice in favor of No. 17-11008</li> </ul>
	Janssen v. Celltrion	No. 16-11117-MLW (D. Mass.)	1	M (cell culture media)	<ul> <li>Dismissed without prejudice in favor of No. 17-11008</li> </ul>
	Janssen v. HyClone	No. 16-00071-BCW (D. Utah)	1	M (cell culture media)	<ul> <li>Case administratively closed November 26, 2019, per related litigation in District of Massachusetts</li> </ul>

### Blockbuster Biologics: US Litigation Scorecard – Remicade (cont.)

<b>Product</b> (# of litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Remicade (5)	Janssen v. Celltrion	No. 17-11008 (D. Mass.) No. 18-2350 (Fed. Cir.) Lead appeal (No. 18-2321)	1	M (cell culture media)	<ul> <li>Judgment entered for defendants after court allowed Motion for Summary Judgment of Noninfringement based on ensnarement</li> <li>Affirmed on appeal</li> </ul>
	Janssen v. Samsung Bioepis	No. 17-3524-MCA-SCM (D.N.J.)	3	Μ	<ul> <li>Janssen voluntarily dismissed its patent infringement claims</li> <li>Suit dismissed with prejudice</li> </ul>

#### Contacts



#### **Christopher J. Betti, Ph.D.** Chicago T: +1.312.324.1449 christopher.betti@morganlewis.com



Maria E. Doukas Chicago T: +1.312.324.1454 maria.doukas@morganlewis.com



Kelly A. Plummer, Ph.D. Chicago T: +1.312.324.1490 kelly.plummer@morganlewis.com